Immune Adverse Events (Iraes) With Adjuvant Ipilimumab In Melanoma, Use Of Hormone Replacement And Immunosuppressants, And Association With Outcome: E1609 Study Analysis

Ahmad A. Tarhini,Sandra J. Lee,Ni Kang,F. Stephen Hodi,Uma N. M. Rao,Gary Irvin Cohen,Lawrence E. Flaherty,Teresa M. Petrella,Vernon K. Sondak,John M. Kirkwood

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 1|浏览59

暂无评分

摘要

60Background: E1609 evaluated adjuvant ipilimumab at 3 mg/kg (ipi3) and 10 mg/kg (ipi10) versus high-dose interferon-α (HDI). In-depth analysis of irAEs and the use of immunosuppressants and hormon...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要